On December 4, 2017 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, reported key presentations of clinical and scientific data related to its products at the 59th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), being held in Atlanta, Georgia, from December 9-12, 2017 (Press release, Spectrum Pharmaceuticals, DEC 4, 2017, View Source [SID1234522353]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For more information about the ASH (Free ASH Whitepaper) annual meeting and for a complete list of abstracts, please refer to the conference website at View Source
The following key PTCL-related abstracts and oral presentations will be presented at the ASH (Free ASH Whitepaper) meeting:
Abstract # Type Title Presenter
Date/Time
Location
342 Oral
The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study
Park Sunday, Dec 10,
8:45 AM
Bldg B, Lvl 4, B401-402
818 Oral Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study Shustov Monday, Dec 11,
4:45 PM
Bldg A, Lvl 4, Marcus Aud.
1455 Poster
North American Adult T Cell Leukemia Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically Targetable Mutations in Epigenetic Modifiers
Shah Saturday, Dec 9,
5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2
2743 Poster
Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl
Scotto Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
380 Poster Direct to Drug Screening as a Route to Individualized Therapy in Multiple Myeloma Meurice Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
4012 Poster Histone Deacetylase Inhibitors Abolish HBZ Protein Expression and Induce Cell Death in HTLV-1 Related Adult T-Cell Leukemia-Lymphoma Ramos Monday, Dec 11,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
4020 Poster Selective Inhibition of HDAC1 and HDAC3 Inhibits Survival of Diffuse Large Cell Lymphoma Via Epigenetic Modulation of Death Associated Protein (DAPK) Gupta Monday, Dec 11
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
The following key EVOMELA (melphalan) for injection-related abstracts will be presented at the ASH (Free ASH Whitepaper) meeting:
Abstract # Type
Title
Presenter
Date/Time
Location
Bldg A, Lvl 1, Hall A2
2023 Poster
Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)
Shah Saturday, Dec 9,
5:30 PM-7:30 PM
3296 Poster Pharmacokinetics and Toxicities after Evomela (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis Shah Sunday, Dec 10,
6:00 PM-8:00 PM
The following key MARQIBO (vinCRIStine sulfate LIPOSOME injection)-related abstracts will be presented at the ASH (Free ASH Whitepaper) meeting:
Abstract # Type Title Presenter
Date/Time
Location
Bldg A, Lvl 1, Hall A2
1549 Poster Excellent Outcome of Elderly Patients with Favourable-Prognosis DLBCL Treated with 4 Cycles CHOP/Chlip-14 Plus 8 Applications of Rituximab and a PET-Based Intensification Strategy That Includes Involved-Site Radiotherapy (IS-RT): Results of the First 120 Patients of the OPTIMAL > 60 Trial of the Dshnhl Pfreundschuh Saturday, Dec 9,
5:30 PM-7:30 PM
1328 Poster Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices LeBlanc Saturday, Dec 9,
5:30 PM-7:30 PM
2554 Poster Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Sasaki Sunday, Dec 10,
6:00 PM-8:00 PM
The following key ZEVALIN (ibritumomab tiuxetan)-related abstracts will be presented at the ASH (Free ASH Whitepaper) meeting:
Abstract #
Type Title Presenter
Date/Time
Location
Bldg A, Lvl 1, Hall A2
1553 Poster A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592) Persky Saturday, Dec 9,
5:30 PM-7:30 PM
4559 Poster Long-Term Follow up of 90y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma Puronen Monday, Dec 11,
6:00 PM-8:00 PM
4066 Poster Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience Agrawal Monday, Dec 11,
6:00 PM-8:00 PM